These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20509712)

  • 1. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
    Drugs R D; 2010; 10(1):25-32. PubMed ID: 20509712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACS chemical neuroscience molecule spotlight on contrave.
    Mercer SL
    ACS Chem Neurosci; 2011 Sep; 2(9):484-6. PubMed ID: 22860172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM
    Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone/bupropion for obesity.
    Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Bello NT
    Expert Opin Drug Saf; 2019 Jul; 18(7):549-552. PubMed ID: 31092063
    [No Abstract]   [Full Text] [Related]  

  • 12. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    Katsiki N; Hatzitolios AI; Mikhailidis DP
    Ann Med; 2011 Jun; 43(4):249-58. PubMed ID: 21254901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
    Plodkowski RA; Nguyen Q; Sundaram U; Nguyen L; Chau DL; St Jeor S
    Expert Opin Pharmacother; 2009 Apr; 10(6):1069-81. PubMed ID: 19364254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
    Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Caixàs A; Albert L; Capel I; Rigla M
    Drug Des Devel Ther; 2014; 8():1419-27. PubMed ID: 25258511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 20. Bupropion/naltrexone fixed-dose combination for the treatment of obesity.
    Halpern B; Faria AM; Halpern A
    Drugs Today (Barc); 2011 Aug; 47(8):575-81. PubMed ID: 21850280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.